PiSA Farmacéutica: Company Profile

Background

Overview

PiSA Farmacéutica is a 100% Mexican pharmaceutical company founded in 1945, with over 80 years of experience in developing, manufacturing, and distributing a wide range of health products. Headquartered in Guadalajara, Jalisco, the company operates 14 production plants across Mexico and employs over 20,000 people. PiSA manufactures more than 1,500 brands of medicines, distributed across 17 therapeutic areas, serving both public and private health sectors in Mexico, the United States, Latin America, and the Caribbean.

Mission and Vision

Mission: To be a responsible, reliable, and ethical group of companies committed to its collaborators and health.

Vision: To achieve permanence through innovation and accelerated growth in Mexico and abroad.

Industry Significance

PiSA Farmacéutica is a leading player in the Mexican pharmaceutical industry, recognized for its extensive product portfolio and commitment to quality. The company has been instrumental in introducing innovative products to the market, addressing critical medical needs, and improving patient outcomes.

Key Strategic Focus

Core Objectives

Maintain leadership in the pharmaceutical industry through continuous innovation and quality.

Expand market presence both domestically and internationally.

Enhance operational efficiency and regulatory compliance.

Areas of Specialization

Manufacturing and distribution of generic and branded medications.

Development of biosimilars and specialized medical devices.

Key Technologies Utilized

Advanced manufacturing technologies, including aseptic filling systems.

Laboratory Information Management Systems (LIMS) for quality control.

Primary Markets Targeted

Mexico

United States

Latin America

Caribbean

Financials and Funding

Funding History

PiSA Farmacéutica is a privately held company and has not publicly disclosed detailed funding history or recent funding rounds.

Financial Performance

Revenue: Estimated to be in the range of $1 billion.

Employees: Approximately 10,000 employees across six continents, including North America, South America, and Europe.

Pipeline Development

Key Pipeline Candidates

PiSA Farmacéutica has a diverse pipeline focusing on various therapeutic areas, including nephrology, oncology, and infectious diseases. The company has developed biosimilars for insulin in partnership with Becton Dickinson AB, an American company.

Stages of Development

Ongoing research and development for new generic formulations.

Clinical trials for biosimilars and specialized medical devices.

Target Conditions

Diabetes

Cancer

Infectious diseases

Anticipated Milestones

Regulatory approvals for new biosimilars.

Market launch of new generic medications.

Technological Platform and Innovation

Proprietary Technologies

Aseptic filling systems for injectable products.

Advanced sterilization techniques for medical devices.

Significant Scientific Methods

Implementation of Laboratory Information Management Systems (LIMS) for quality control.

Adoption of lean manufacturing principles to enhance operational efficiency.

Leadership Team

Key Executives

Carlos Álvarez Bermejillo: President and CEO.

Professional Background: Over 30 years of experience in the pharmaceutical industry, leading PiSA Farmacéutica through significant growth and innovation.

Key Contributions: Spearheaded the expansion into international markets and the development of biosimilars.

Leadership Changes

No recent significant changes or appointments within the company's leadership have been publicly disclosed.

Competitor Profile

Market Insights and Dynamics

The Mexican pharmaceutical market is characterized by a growing demand for generic medications, with generics constituting nearly 83% of the total pharmaceutical market in 2022. The market is also witnessing increased competition among domestic manufacturers and evolving regulatory landscapes.

Competitor Analysis

Grupo Farmacéutico Somar: Holds a market share of about 10%, recognized for its extensive portfolio of generics.

Laboratorios Pisa: A subsidiary of PiSA Farmacéutica, specializing in various therapeutic areas, including neurology.

Genomma Lab Internacional: A prominent player in the Mexican pharmaceutical market, particularly in OTC and prescription generics.

Strategic Collaborations and Partnerships

PiSA Farmacéutica has engaged in strategic partnerships, including the development of biosimilars for insulin in collaboration with Becton Dickinson AB.

Operational Insights

PiSA Farmacéutica's extensive manufacturing capabilities, including 14 production plants across Mexico, provide a competitive advantage in meeting both domestic and international demand.

Strategic Opportunities and Future Directions

The company's focus on innovation, quality, and expansion into international markets positions it well to capitalize on the growing demand for generic medications and specialized medical devices.